Loading…
← CockpitCompetitor Analysis › CORT Corcept Therapeutics Incorporated.Open in the cockpit ↗

Corcept Therapeutics Incorporated.CORTCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Biotech specializing in cortisol-modulating drugs, selling Korlym for Cushing's syndrome and developing relacorilant.

Momentum laggard 18
Mkt cap
$7.42B
US dollars, full cap
Free float
89%
of shares outstanding
$/day
$109M
20-day average traded
Fwd P/E
15.3×
forward earnings
ROIC−WACC
+10.8 pp
WACC 7.7%
Hurdle
+7 pp
Req g minus delivered
Next earnings
104 days
2 Mar 2027
Close · USD$67.79
1D-3.2%
1W-9.0%
1M-41.8%
3M-44.0%
6M+14.8%
YTD+94.8%
1Y-9.8%
ATR %7.5%
Beta1.76
52w lowhigh46.4% off high

What Corcept Therapeutics does

Biotech specializing in cortisol-modulating drugs, selling Korlym for Cushing's syndrome and developing relacorilant.

Nearly all revenue is Korlym, sold in the US through a small number of specialty pharmacies to patients with Cushing's syndrome (too much cortisol), and a generic version has been on sale since 2024. Relacorilant, from the same cortisol-blocking family, is the planned successor, funded from Korlym's profits.

Products and services

  • Korlym (Cushing's syndrome)
  • Relacorilant (pipeline, Cushing's/oncology)

Customers

  • Endocrinologists
  • Oncologists (pipeline)
  • Payers

Where it sits in the supply chain

  • Pharmaceuticals
  • Biotech
  • Endocrinology - cortisol/Cushing's…

What could go right

  • Relacorilant approval expanding the addressable market
  • Growing Cushing's syndrome diagnosis rates

What could go wrong

  • Heavy reliance on a single approved drug (Korlym)
  • Patent-litigation and generic-entry risk

Moat: narrow (IP / patents, process know-how). Deep expertise in cortisol-receptor biology and years of prescriber education in a niche disease.

Headquarters: Menlo Park, California, United States · Founded: 1998 · Employees: 730

Named competitors

Corcept Therapeutics at a glance

Size Corcept Therapeutics (CORT) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $7.42B, the 923rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $67.79 on 18 Nov 2026.

Performance Over six months the shares gained 14.8%, against -0.4% for the median peer and -2.2% for the United States market (cap-weighted) — 8th highest of 20 in its peer set.

Growth Revenue grew 30.0% over the last twelve months (peer median +10.7%); the operating margin is 11.5% (peer median 15.1%).

Valuation It trades at 15.3× forward earnings against a peer median of 19.3× (6th cheapest of 16).

Price implies For today's price to make sense, revenue must grow about 24% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 10.8 points above its cost of capital (7.7% WACC).

Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026CORT 114Peer median 102
Six months, rebased to 100: Corcept Therapeutics against the median of its 20 peers (local-currency closes).

Corcept Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$964M$761M$675M$482M$402M
Revenue growth—+13%+40%+20%—
Gross profit$950M$748M$664M$476M$396M
EBITDA$114M$46.7M$138M$108M$116M
Net income$159M$98.2M$140M$105M$101M
Free cash flow$195M$142M$196M$127M$120M
Capital expenditure$3.49M$211,000$2.17M$139,000$413,000
Total debt$8.99M$6.11M$6.94M$151,000$1.14M

Quarterly statements and history in the cockpit →

Corcept Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-25%0%+25%KNSAGRF4528600196002821AMRXCYTKIBRXBANB9926ALKSALK-BGLENMARKRYTMPTGX000999CORT6-month return →1-month return →
Up and to the right = strong over both horizons. Corcept Therapeutics is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%0×500×1,000×1,500×KNSAGRF4528002821ALK-BPTGXCORTRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Corcept Therapeutics is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%KNSAGRF4528600196AMRXALKSALK-BGLENMARK000963ALKEM601607PTGX000999APTXCORTGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Corcept Therapeutics is the large dot.

Corcept Therapeutics competitors and peer comparison

Head to head with its named competitors (CORT vs NOVN.SW vs REC.MI vs XERS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Corcept Therapeutics CORT$7.42B+15%+30%12%15.3×23.9%
Novartis NOVN.SW$285B+11%-4%30%17.5×1.6%
Recordati REC.MI$12.0B+3%+8%30%16.6×1.1%
Xeris Biopharma XERS$3.10B+173%+38%13%49.7×29.5%
Teva Pharmaceutical Industries Limited Sponsored ADR TEVA$49.3B+23%-4%19%15.0×10.5%

How Corcept Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Corcept Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureCORTPeer medianRank in peer set
1-month return-41.8%+2.2%lowest of 21
6-month return+14.8%-0.4%8th highest of 20
Distance from 52-week high-46.4%-11.2%2nd lowest of 21
Revenue growth (TTM)+30.0%+10.7%6th highest of 21
Operating margin11.5%15.1%9th lowest of 21
Forward P/E15.3×19.3×6th cheapest of 16
Growth the price implies (Req g, 7 yrs)23.9%7.2%4th most demanding of 15
Growth delivered (Del g)+16.6%+9.0%3rd highest of 15
Hurdle (Req g minus delivered)+7.4 pp-4.5 pp6th most demanding of 15
ROIC minus cost of capital+10.8 pp+1.7 pp5th highest of 19
EV / EBITDA62.0×22.6×most expensive of 12
Net debt / EBITDA-3.2×0.6×2nd least indebted of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Corcept Therapeutics CORTUnited States$7.42B+15%+30%12%15.3×23.9%+16.6%
Kiniksa Pharmaceuticals International KNSAUnited States$7.47B+75%+58%14%56.6×10.4%+45.5%
Grifols GRF.MCSpain$7.48B+19%+1%16%13.1×7.1%+7.1%
ONO Pharmaceutical 4528.TJapan$7.33B-2%-2%22%15.3×-6.8%+10.8%
Shanghai Fosun Pharmaceutical (Group) 600196.SSChina$7.57B-14%+8%6%14.8×2.9%+6.6%
Asymchem Laboratories (Tianjin) 002821.SZChina$7.27B+20%+18%17%37.4×n/an/a
Amneal Pharmaceuticals AMRXUnited States$7.62B+79%+9%16%19.2×17.2%+8.7%
Cytokinetics CYTKUnited States$7.15B-35%+30%-625%n/an/an/a
ImmunityBio IBRXUnited States$7.13B-17%+121%-150%n/an/an/a
Bachem BANB.SWSwitzerland$7.06B0%+5%19%32.4×n/an/a
Akeso 9926.HKHong Kong$7.01B-48%+42%-25%n/an/an/a
Alkermes Public ALKSUnited States$7.87B+27%+15%5%n/a32.5%+7.3%
ALK-abello A/S ALK-B.CODenmark$7.94B-8%+16%26%34.8×7.3%+12.6%
Glenmark Pharmaceuticals GLENMARK.NSIndia$7.98B+10%0%17%33.1×27.3%+9.4%
Huadong Medicine 000963.SZChina$6.69B-18%+2%9%12.5×-3.9%+5.3%
Alkem Laboratories ALKEM.NSIndia$6.69B-5%+13%17%27.3×25.0%+10.7%
Shanghai Pharmaceuticals 601607.SSChina$8.23B0%+4%3%11.2×-10.1%+8.1%
Rhythm Pharmaceuticals RYTMUnited States$8.25B+31%+61%-67%n/an/an/a
Protagonist Therapeutics PTGXUnited States$8.30B+26%+164%59%1,532.5×17.5%+10.0%
China Resources Sanjiu Medical & Pharmaceutical 000999.SZChina$6.59B+6%+4%14%13.2×-6.2%+18.4%
Apotex Health APTX.TOCanada$6.56Bn/a+4%32%19.3×-11.9%+4.2%

Questions

Who are Corcept Therapeutics's main competitors?
Named competitors: Novartis (NOVN.SW), Recordati (REC.MI), Sparrow Pharmaceuticals (private or unlisted), Xeris Biopharma (XERS), Teva Pharmaceutical (TEVA). The cockpit's measured peer set (industry) also includes Kiniksa Pharmaceuticals International (KNSA), Grifols (GRF.MC), ONO Pharmaceutical (4528.T), Shanghai Fosun Pharmaceutical (Group) (600196.SS), Asymchem Laboratories (Tianjin) (002821.SZ), Amneal Pharmaceuticals (AMRX).
Is Corcept Therapeutics expensive compared with its peers?
On forward p/e it trades at 15.3× against a peer median of 19.3×, 6th cheapest of 16 in its peer set. For today's price to make sense, revenue must grow about 24% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Corcept Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned +14.8% against -0.4% for the median peer; over one year -9.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.